Abstract: The present invention is a film formed from an acrylate blend. The preferred blend is a film comprising components (a) and (b), component (a) being an ethylene butyl acrylate copolymer (EBAC) which is less than about 95 percent percent by weight of a total weight of components (a) and (b), wherein the EBAC has a content of acrylate groups from about 8 to about 36 percent by weight of the total weight of the EBAC; and component (b) being an ethylene methyl acrylate copolymer (EMAC) which is greater than about 5 percent by weight of the total weight of components (a) and (b), wherein the EMAC has a content of acrylate groups from about 8 to about 42 percent by weight of the total weight of the EMAC.

Abstract: The present invention is a film formed from an acrylate blend. The preferred blend is a film comprising components (a) and (b), component (a) being an ethylene butyl acrylate copolymer (EBAC) which is less than about 95 percent percent by weight of a total weight of components (a) and (b), wherein the EBAC has a content of acrylate groups from about 8 to about 36 percent by weight of the total weight of the EBAC; and component (b) being an ethylene methyl acrylate copolymer (EMAC) which is greater than about 5 percent by weight of the total weight of components (a) and (b), wherein the EMAC has a content of acrylate groups from about 8 to about 42 percent by weight of the total weight of the EMAC.

Abstract: A method to detect invalid polygons that are inputted by users using a graphical user-interface is presented. The method selects pairs of lines that are used to define the polygon and tests to determine if the lines crossover. If there are no crossovers, then the polygon is a valid polygon. If there is a pair of lines that do crossover one another, then the polygon is an invalid polygon. Such a method is useful in teaching polygons and their properties to novices and students.

Abstract: The invention is directed to non-hygroscopic oral pharmaceutical compositions of a salt of valproic acid, and processes for preparing the compositions. The non-hygroscopic pharmaceutical compositions are prepared by blending a hygroscopic salt of valproic acid, carbomer, and a non-hygroscopic additive.

Abstract: Pharmaceutical gastroretentive drug delivery systems for the controlled release of an active agent in the gastrointestinal tract are disclosed, which comprise: (a) a single- or multi-layered matrix comprising a polymer that does not retain in the stomach more than a conventional dosage form selected from (1) degradable polymers that may be hydrophilic polymers not instantly soluble in gastric fluids, enteric polymers substantially insoluble at pH less than 5.5 and/or hydrophobic polymers and mixtures thereof; (2) non-degradable polymers; and any mixtures of (1) and (2); (b) a continuous or non-continuous membrane comprising at least one polymer having a substantial mechanical strength; and (c) a drug; wherein the matrix when affixed or attached to the membrane prevents evacuation from the stomach of the delivery system for a period of time of from about 3 to about 24 hours.

Abstract: A universal console (UC) platform for a UC device is provided. The user sets up or initializes the UC by describing his or her preferences and disabilities. The UC digests and stores this user information. Later, as the user encounters various devices and applications to be controlled, and indicates a desire to control a particular device, the device to be controlled or other source sends a canonical user interface (UI) description of the device's UI to the UC. The canonical UI description adheres to an abstract format to describe in high-level terms the functionality of the device's UI.

Abstract: The invention provides a process for preparing a non-hygroscopic, highly stable, oral pharmaceutical composition of a salt of valproic acid. The pharmaceutical composition is prepared by blending ingredients including a hygroscopic salt of valproic acid, carbomer, and a non-hygroscopic additive such as dibasic calcium phosphate. Such a composition forms non-hygroscopic, highly moisture stable solid dosage form.

Abstract: A clear multilayer film for coating synthetic environmental surfaces includes an exposed protective layer and an underlying cushioning layer. The exposed layer is primarily a polymer blend of a fluorine substituted olefin polymer, such as polyvinylidene fluoride, with an acrylic polymer. The cushioning layer is of a low modulus polymer selected from among impact modified acrylic polymer, ethylene vinyl acetate polymer and metallocene catalyzed polyethylene and having an elastic modulus below about 30,000 psi (207 MPa). The cushioning layer should be substantially free of all fluorinated polymers. The multilayer film can have an optional additional thermally adhesive layer of a blend of a fluorine substituted olefin polymer with an acrylic polymer. The multi layer film offers superior protection to such substrates as outdoor building siding, vehicle body panels, and signs from stains, weather conditions, and especially impact damage.

Abstract: An optically transparent glazing measures about 3 to 5 mm in total thickness, and has an interlayer film, the interlayer film comprises at least two polymeric film layers: a core film layer having a modulus of at least 25,000 psi (173 MPa) and a surface film layer having a maximum modulus of 15,000 (104 MPa) at 50 to 10,000 Hz and 20° C.; and the glazing is characterized by an acoustical barrier insulating capacity at least equivalent to that of a 3.85 mm thick monolithic pane of glass. The glazing also has an Articulation Index value of less than 64.2% at 50 to 10,000 Hz, a sharpness value of less than 150 at 50 to 10,000 Hz, a penetration resistance of at least 9 meters in test method ECE R43, A6 4.2, and a maximum haze of 4%. The interlayer film has a bending stiffness of at least 0.01 Pa*m3. The surface film layer has a maximum tan delta of 0.6 at 50 to 10,000 Hz and 20° C. The interlayer film preferably comprises one core film layer of between 1.0 and 1.

Abstract: High clarity optical and safety glass laminate interlayer films and optical laminates are described. The films and their laminates comprise very low density polyethylene and/or its copolymers, preferably polymerized with metallocene catalysts, and modified with additives, such as coupling agents, clarifying or nucleation agents, UV-light absorbers, pigment or color concentrate, and IR-light blockers. The very low density polyethylene is laminated to EVA film for improved bondability in optical laminates.

Abstract: The present invention relates to a pharmaceutical controlled-release oral drug delivery system comprising as active ingredient at least one &bgr;-lactam antibiotic agent, having a specific absorption site in the small intestine in combination with a polymeric matrix, optionally further containing additional pharmaceutically acceptable constituents, wherein at least 50% of the &bgr;-lactam antibiotic agent are released from the matrix within from about 3 to about 4 hours from oral administration and the reminder of the pharmaceutical agent is released at a controlled rate. The drug delivery system according to the invention optionally further comprises a &bgr;-lactamase inhibitor, preferably in combination with amoxicillin and/or amoxicillin trihydrate as the active ingredient. The polymeric matrix of the pharmaceutical controlled-release oral drug delivery system of the invention my be of hydrophilic and/or hydrophobic nature and the delivery system may further comprise pharmaceutically acceptable additive.

Abstract: A computer-implemented modeling, or planning, system provides a graphical user interface including a timeframe. Under user control, instances of component objects representing modeling entities can be displayed with respect to the timeframe for the input of time-related properties for the component objects. The component objects provide calculations in response to the time-related properties on properties of the component object for deriving an output comprising a time-series of output values. A resulting report can be generated based on the time-series of output values. The displayed instances of the component objects can be directly manipulated by the user in order to define the time-related properties. The direct graphical representation facilitates planning operations and enables accurate, rapid and easily understandable development of plans. Multiple scenarios can easily be generated using the system. A revision mechanism facilitates the return to a scenario modeled earlier.

Abstract: A computer-implemented modeling, or planning, system provides a graphical user interface including a timeframe. Under user control, instances of component objects representing modeling entities can be displayed with respect to the timeframe for the input of time-related properties for the component objects. The component objects provide calculations in response to the time-related properties on properties of the component object for deriving an output comprising a time-series of output values. A resulting report can be generated based on the time-series of output values. The displayed instances of the component objects can be directly manipulated by the user in order to define the time-related properties. The direct graphical representation facilitates planning operations and enables accurate, rapid and easily understandable development of plans. Multiple scenarios can easily be generated using the system. A revision mechanism facilitates the return to a scenario modeled earlier.

Abstract: A zero-order sustained-release delivery system for delivery of carbamazepine or a derivative thereof. A polymeric matrix formulation of carbamazepine comprises hydrophilic polymer or hydrophilic/hydropholic polymer mixture which permits carbamazepine or carbamezepine derivative to be released from the polymer matrix in zero-order release kinetics.

Abstract: An anti-fungal composition, including: (a) an extract of botanical materials, the botanical materials including material from Echinacea species, and Propolis, which is a material derived from the hives of bees; and (b) an essential oil. The compositions of the present invention have been shown to have unexpectedly prolonged anti-fungal activity, as well as having anti-bacterial and anti-inflammatory activities. Preferably, the essential oil includes at least one oil selected from the group consisting of tea-tree oil, thyme oil and lavander oil. Also preferably, the herbal extract includes a mixture of Calendula, poke root, Echinacea and Propolis extract.

Abstract: The present invention provides a pharmaceutical preparation in tablet form, where the active ingredient is an anti-epileptic medication, preferably a sustained release formulation, and most preferably a sustained release formulation where the active ingredient is carbamazepine. The product consists of carbamazepine particles coated with a single hydrophobic layer and is in a disintegrating tablet form.

Abstract: High clarity optical and safety glass laminate interlayer films and optical laminates are described. The films and their laminates comprise very low density polyethylene and/or its copolymers, preferably polymerized with metallocene catalysts, and modified with additives, such as coupling agents, clarifying or nucleation agents, UV-light absorbers, pigment or color concentrate, and IR-light blockers. The very low density polyethylene is laminated to EVA film for improved bondability in optical laminates.

Abstract: Compositions comprising a blend of a MPEP (metallocene catalyzed polyethylene plastomer) and a MPEE (metallocene catalyzed olefin copolymer elastomer); self-adhering film materials made from a blend of these metallocene polymers; and methods of making these self-adhering film materials which are useful for sealing and wrapping applications.

Abstract: A synergistic anti-bacterial composition, including: (a) an extract of botanical materials, the botanical materials including material from Plantago species, Hypericum species, Echinacea species and Propolis; and (b) oil of cinnamon.

Abstract: The invention relates to an oral composition for prevention of mycotic infections of the oral cavity comprising an antifungal compound embedded in a sustained release carrier such as a cellulosic polymer, and a method for the use of said composition in preventing microfungal infections in the oral cavity. The invention also provides for the supplementation of said oral composition with an adhesive and a plasticizer to increase antifungal effectiveness.